| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 1. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | galantamine (Reminyl® XL) |
| Formulation | 8 mg, 16 mg and 24 mg prolonged-release capsule |
| Reference number | 154 |
| Indication | Symptomatic treatment of mild to moderately severe dementia of the Alzheimer type |
| Company | Shire Pharmaceuticals Ltd |
| BNF chapter | Central nervous system |
| Assessment type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 18/01/2005 |